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Abstract
In Western societies a considerable percentage of young people expose themselves to the combination of 3,4-methylenedioxymethamphetamine (MDMA
or ‘ecstasy’) and cannabis. The aim of the present study was to assess the acute effects of co-administration of MDMA and THC (the main psychoactive
compound of cannabis) on pharmacokinetics, psychomotor performance, memory and subjective experience over time. We performed a four-way, double
blind, randomized, crossover, placebo-controlled study in 16 healthy volunteers (12 male, four female) between the ages of 18 and 27. MDMA (100mg)
was given orally, THC (4, 6, and 6mg, interval of 90min) was vaporized and inhaled. THC induced more robust cognitive impairment compared with
MDMA, and co-administration did not exacerbate single drug effects on cognitive function. However, co-administration of THC with MDMA increased
desired subjective drug effects and drug strength compared with the MDMA condition, which may explain the widespread use of this combination.
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Introduction
In Western societies, a signiﬁcant proportion of young people
expose themselves to 3,4-methylenedioxymethamphetamine
(MDMA or ‘ecstasy’) (Parrott, 2001). Ecstasy users are gen-
erally multidrug users, having experience with diﬀerent psy-
choactive substances and combining them with ecstasy
(Gouzoulis-Mayfrank and Daumann, 2006). Cannabis
(main active compound 9-tetrahydrocannabinol or THC)
is frequently co-used with ecstasy (Parrott et al., 2007).
While 90–98% of ecstasy users also use cannabis (Parrott
et al., 2007), Winstock et al. (2001) showed that 82% of
ecstasy users had used cannabis concurrently with ecstasy at
least once. Boys et al. (2001) reported that out of 177 ecstasy
users, 55 (31%) used cannabis concurrently in the last year to
‘enhance the eﬀects’ of ecstasy and 114 (64%) used cannabis
concurrently in the last year to ‘ease the after eﬀects’ of
ecstasy. Despite the prevalence of co-administration of
MDMA and THC, the eﬀects of combined use of these sub-
stances in humans have so far not been investigated.
MDMA releases serotonin (5-HT) from presynaptic
5-HT terminals by reversal of the reuptake transporter and
thus increases 5-HT levels at the postsynaptic receptors
(Liechti and Vollenweider, 2000; Mlinar and Corradetti,
2003; Piﬂ et al., 1995). MDMA is also a potent releaser of
dopamine and (nor) adrenaline (Colado et al., 2004; Liechti
and Vollenweider, 2001; Sprague et al., 2004). In a previous
study by our group, MDMA was found to increase psycho-
motor speed without aﬀecting psychomotor accuracy.
MDMA impaired the delayed recall of words, whereas
word recognition was unaﬀected. MDMA increased subjec-
tive arousal and decreased subjective calmness (Dumont
et al., 2008). Other studies regarding the cognitive eﬀects
of MDMA are generally in agreement with these ﬁndings
(Hernandez-Lopez et al., 2002; Kuypers and Ramaekers,
2005, 2007; Dumont and Verkes, 2006). These eﬀects gener-
ally coincided with maximal MDMA plasma concentration
but declined to baseline values 5–6 h after drug administration
in spite of persisting MDMA plasma concentration, which is
generally consistent with the literature (Dumont and Verkes,
2006). MDMA is rapidly absorbed following oral administra-
tion, and within 30min is detectable in the blood. MDMA
plasma levels peak 1–2 h after drug intake.
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THC, the major psychoactive compound in cannabis (Ilan
et al., 2005; Wachtel et al., 2002), is an agonist for the CB1
and CB2 receptors of the endocannabinoid system (ECS). The
CB1 receptor is abundantly expressed in the central nervous
system whereas the CB2 receptor is expressed predominantly
in the periphery (Ameri, 1999). The central eﬀects of THC
have received abundant attention in the scientiﬁc literature
and generally include, but are not restricted to, impairment
of memory and psychomotor function and subjective relaxa-
tion (Ranganathan and D’Souza, 2006). A recent review
revealed that cannabis aﬀects most functional central nervous
system domains, but because of great variations in study
methodology only increases of heart rate and subjective feel-
ings (feeling ‘high’) were found to be reliable biomarkers of
cannabis eﬀects (Zuurman et al., 2009). THC, a highly lipo-
philic compound, is rapidly distributed into fatty tissue, and
after inhalation, peak plasma concentration are reached
within minutes and show a rapid decline, although cognitive
eﬀects and subjective eﬀects are maximal after 15–60min
and last for several hours (Strougo et al., 2008; Zuurman
et al., 2008).
As combined use of MDMA and THC is common
(Parrott et al., 2004, 2007), and these substances both aﬀect
memory as well as psychomotor function, we aimed to assess
the cognitive and subjective eﬀects of co-administration of
MDMA, a potent serotonin releaser, and THC, a CB1 ago-
nist, over time under controlled laboratory conditions in
experienced users. Previous research regarding the cognitive
eﬀects of co-administration of MDMA and THC is limited to
a study in rats and showed that co-administration induced a
synergistic impairment of working memory (Young et al.,
2005). Thus, co-administration was expected to show addi-
tive impairment of memory, whereas eﬀects on psychomotor
performance were expected to be attenuated because of
the opposing actions of the stimulant MDMA and the relax-
ant THC.
Materials and methods
Study design
This study utilized a four-way, double blind, randomized,
crossover and placebo-controlled design, and was conducted
according to the principles of the Declaration of Helsinki.
Each volunteer received a capsule containing either MDMA
100mg or placebo and inhaled a vapour containing consecu-
tively 4, 6 and 6mg of THC (dosing intervals of 90min) or
placebo vapour containing vehicle with a washout of 7 days
between each condition. The present manuscript addresses
the cognitive eﬀects of this drug combination; this study
also assessed physiological eﬀects, which have been published
elsewhere (Dumont et al., 2009).
Study outline
Subjects were admitted to each study day after a urinary
drug check (opiates, cocaine, benzodiazepines, amphet-
amines, methamphetamines and THC, AccuSign,
Princeton BioMeditech, Princeton, NJ, USA: drug use was
not allowed 14 days prior to the ﬁrst study day until study
completion) and the recording of possible signs and symp-
toms of health problems. As THC was administered during
study days, urine positive for THC led to exclusion only on
study day 1. A light breakfast was oﬀered 2 h prior to
MDMA administration. MDMA administration was sched-
uled at 10 : 30 h and THC was administered at 0, 90 and
180min after MDMA administration. It is unknown which
order of recreational MDMA and THC use is most common.
This administration schedule was chosen because it allows
assessing the eﬀects of the acute combinations of
THCþMDMA, the addition of THC at the peak of
MDMA eﬀects or the addition of THC at the descending
slope of MDMA eﬀects. Subjects received a standardized
lunch at 14 : 00 h and were sent home around 17 : 00 h.
Outcome measures were assessed repeatedly, that is,
before MDMA administration and at 15, 60, 105, 150, 240
and 300min post-drug administration, with the exception of
the 18 word list memory task, which was performed 120min
after drug administration. Repeated measures consisted of
blood sampling for analysis of MDMA kinetics and assess-
ments of postural stability, psychomotor function, memory
and subjective eﬀects as speciﬁed below. Pharmacokinetic
data has been reported in detail elsewhere (Dumont et al.,
2009). To familiarize the subjects with the tests and proce-
dures, they performed a practice session 1week before the
actual study days.
Subjects
Sixteen healthy volunteers (12 male, four female), regular
users of ecstasy (at least eight exposures in the last 2 years)
and THC (on average two exposures per week in the last
year), between the ages of 18 and 27, were recruited through
advertisement on the Internet and at local drug testing ser-
vices. Detailed demographic data are shown in Table 1.
Table 1. Demographic data of study participants, drug use is quantified
as the cumulative number of lifetime drug exposures (not further
specified)
Mean SEM Min Max
Age (years) 21 0.5 18 27
Education (years) 16 0.3 12 18
Height (cm) 178 1.7 165 189
Weight (kg) 71 2.1 60 86
Opiates 26 9 1 50
LSD 33 13 2 108
Ecstasy 143 53 10 702
Amphetamines 96 50 1 624
Cannabis 1716 429 364 6570
Cocaine 46 19 2 234
Alcohol 6071 1221 144 15,600
Solvents 122 70 1 834
Benzodiazepines 7 3 1 25
Psilocybin 19 6 1 60
GHB 33 19 1 208
Ketamine 211 116 1 1040
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Exclusion criteria included pregnancy, (history of) psy-
chiatric illness [assessed using the Structured Clinical
Interview for DSM-IV axis I disorders, non-patient version
(First et al., 1994); Axis II disorders were excluded using the
Temperament and Character Inventory (Svrakic et al., 1993)],
use of over-the-counter medication within 2months prior to
the study start (history of) treatment for addiction problems,
excessive smoking (>10 cigarettes/day) and orthostatic dysre-
gulation. Physical and mental health was determined by
assessment of medical history, a physical and electrocardio-
graphic examination as well as standard haematological and
chemical blood examinations. The local medical ethics com-
mittee approved the study. All subjects gave their written
informed consent before participating in the study, and
were paid for their participation.
One subject did not refrain from drug use, after which
further study participation was denied. Two subjects experi-
enced an adverse event that was judged to be likely related to
study drug administration [one subject experienced a short
(lasting 55 s) heart rate increase of >180 bpm and another
subject experienced mild hallucinations, the latter subsiding
along with other drug eﬀects]. These subjects were excluded
from further participation; data of completed study days
obtained prior to these adverse events were analysed as
described.
Study drugs
THC was puriﬁed according to Good Manufacturing Practice
(GMP)-compliant procedures (Farmalyse BV, Zaandam, The
Netherlands) from the ﬂowers of Cannabis sativa grown
under Good Agricultural Practice (Bedrocan BV Medicinal
Cannabis, Veendam, The Netherlands) (Choi et al., 2004;
Hazekamp et al., 2004). Each dose (4, 6 and 6mg) of THC
[>98% purity by high-performance liquid chromatography
(HPLC)/gas chromatography] was dissolved in 200 ml 100
vol% alcohol. THC was stored in the dark at 20C in
1-ml amber glass vials containing a Teﬂon screw cap secured
with Para ﬁlm to minimize evaporation. The solvent was used
as placebo.
On each study day, THC (4, 6 and 6mg) or placebo
were administered by inhalation at 90-min intervals using
a Volcano vaporizer (Storz-Bickel GmbH, Tu¨ttlingen,
Germany), a validated method of intrapulmonary THC
administration (Abrams et al., 2007; Hazekamp et al.,
2006). Concurrent with MDMA administration, THC
(4mg) was administered to ensure tolerability. Ninety and
180min after drug administration, 6mg of THC was admin-
istered. Within 5min before administration, THC was vapor-
ized at a temperature of about 225C and the vapour was
stored in a polythene bag equipped with a valved mouth-
piece, preventing the loss of THC in between inhalations.
The transparent bag was covered with a black plastic bag to
prevent unblinding. Subjects were not allowed to speak, and
were instructed to inhale deeply and hold their breath for 10 s
after each inhalation. Within 2–3min, the bag was to be fully
emptied. The inhalation procedure was practised at screening
using the vehicle only.
Each 6-mg THC dose was predicted to cause THC plasma
concentrations and eﬀects that roughly correspond to those of
one marijuana cigarette (Zuurman et al., 2008). The decision
to proceed to the next THC dose was made by a physician,
based on adverse events and physical signs.
MDMA (or matched placebo) was given as a capsule in a
single oral dose of 100mg. MDMA was obtained from
Lipomed AG (Arlesheim, Switzerland) and encapsulated
according to GMP by the Department of Clinical Pharmacy
of Radboud University Nijmegen Medical Centre.
Pharmacokinetic measurements
THC. For determination of the concentration of plasma THC
and its two most important metabolites (11-OH-THC and 11-
nor-9-carboxy-THC), venous blood was collected in EDTA
tubes of 4.5ml covered with aluminium foil. Blood samples
were taken 5 and 20min after each THC administration and
immediately put on ice and were processed (spun at 1500 g for
10min at 4C) within 30min after collection. THC blood
samples were handled sheltered from light. Plasma samples
were stored at a temperature of 80C for less than 3months
before laboratory analysis. Concentrations of THC and the
metabolites were shown to be stable over this period
(Hazekamp et al., 2004).
Determination of THC, 11-OH-THC and 11-nor-
9-carboxy-THC content was performed using a validated
HPLC with tandem mass spectrometric detection. The cali-
bration range was 1.00–500 ng/ml for all compounds. Over
this range, the intra-assay coeﬃcient of variation was between
4.0% and 6.5%. The inter-assay coeﬃcient of variation was
between 1.4% and 9.4%.
MDMA. An HPLC–diode array detection method was
employed to assess MDMA and methylenedioxyampheta-
mine (MDA) plasma concentration, which has been described
in detail previously (Dumont et al., 2008).
Pharmacodynamic measurements
Eye movements. Saccadic eye movements are a measure for
psychomotor speed and sedation. Eye movements were quan-
tiﬁed by recordings of ﬁeld potential changes related to eye
rotations. Similar to EEG patterns and the architecture of
evoked potentials in rats (Meeren et al., 1998), saccadic
motion is dependent on the state of alertness (van
Steveninck et al., 1999). For the saccadic test, which lasted
1.5min, the subject was instructed to look at a target that
suddenly changed position at random intervals. The target
consisted of an array of light-emitting diodes on a bar ﬁxed
at 50 cm in front of the head support. Each recording session
consisted of 15 saccades of 15 stimulus amplitudes. The out-
come measures are peak saccadic velocity and reaction time.
For smooth pursuit eye movements, a measure of psycho-
motor accuracy, the target moved sinusoidally at frequencies
ranging from 0.3 to 1.1Hz, by steps of 0.1Hz during 60 s. The
amplitude of target displacement corresponded to 20 of eye-
ball rotation to both sides. The time in which the eyes were in
smooth pursuit of the target was calculated for each fre-
quency and expressed as a percentage.
Saccadic and smooth pursuit eye movements were
recorded using Nihon-Kohden and Cambridge Electronics
Design (CED) hardware, and CED Spike2 software for
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sampling and analysis of eye movements. Eﬀects on the sac-
cadic eye movements, the saccadic eye velocity (PV), were
analysed according to published rules (Meeren et al., 1998;
Sundstrom and Backstrom, 1998). Head movements were
restrained using a ﬁxed head support. Eye movements are
used to locate objects and predict the path of moving objects,
and as such can be expected to be relevant for driving related
abilities (Orban de Xivry and Lefevre, 2007). Moreover, they
are sensitive to the eﬀects of serotonergic challenges, MDMA
and cannabis (Dumont et al., 2007; Gijsman et al., 2002;
Zuurman et al., 2008).
Body sway. Subjects were asked to close their eyes while in
an upright position and were attached to the body sway appa-
ratus that records cumulative horizontal body movement (in
mm) for 2min. The test is a measure for postural stability
(Wright, 1971).
Pursuit task. To measure implicit procedural learning, a
computerized version of the rotor pursuit task was used. This
test is based on the classic rotary pursuit task (Ammons,
1951). It is a continuous motor task. Subjects had to follow
the movement of a large target stimulus on the computer
screen with a cursor by moving the pen over a X–Y-tablet.
The speed of the target gradually increased when the cursor
was contained within the target but decreased considerably
when it was not. The target followed a spatially predictable
circular path over the screen. The outcome measure for this
test was the total number of rotations within 2min.
Eighteen words list. The 18 words list is a verbal memory
test based on the classic Auditory Verbal Learning Test
(Vakil and Blachstein, 1993). A variant was made consisting
of a list of 18 words. The classic test uses 15 words. A longer
word list was chosen to prevent ceiling eﬀects. The list was
presented verbally three times 120min after MDMA admin-
istration (30min after the second THC administration).
Under normal circumstances, subjects are supposed to
remember an increasing number of words after each trial.
Directly after each presentation, and after an interval of
20min, subjects were asked to recall as many words as pos-
sible. After the delayed recall trial a list of 36 words was
presented, from which they were asked to recognize the 18
words previously presented. The incorrect words were distrac-
ters and resembled the correct words in a semantic or phono-
logical manner. Responses were either correct positive (when
a word that was recognized was indeed part of the list pre-
sented during immediate recall) or false positive (when a word
was recognized but was not part of the list presented during
immediate recall, e.g. the word was a distracter). The outcome
measure was the number of correctly recalled/recognized
words for the average of the three immediate recall trials,
the delayed recall trial and the delayed recognition trial (cor-
rect positive and false positive).
N-back task. The N-back task, a test of working memory,
is widely used for the detection of working memory deﬁcits
(Meyer-Lindenberg et al., 2001). Subjects were presented with
a starting circle and six possible target circles surrounding the
starting circle on the screen, reﬂecting the same positions as
on the paper form. In the 1-back condition, subjects had to
respond to the stimulus, that is, move the pen into the target
circle, which lit up in the previous trial. In the 2-back
condition, subjects had to respond to the stimulus presented
two trials before. In the 3-back condition, subjects had to
respond to the stimulus presented three trials before. The out-
come measure was the time needed until completion of 25
correct trials.
Bond and Lader (Visual Analogue) Mood Rating Scale
(BLMRS). The BLMRS scale consists of 16 lines, each
10 cm in length, with opposite terms at each end of the line
(Bond et al., 1974). Subjects were asked to indicate which item
was more appropriate by marking the line. The outcome mea-
sure of these visual analogue scales was the distance to the
marker on each scale. These scale scores were aggregated to
scores for ‘calmness’, ‘alertness’ and ‘contentedness’, as
described by Bond et al. (1974).
Subjective drug experience visual analogue scales. To assess
subjective drug experience and motivation, three visual ana-
logue scales were constructed (drug liking, drug strength and
motivation, 0 being minimal and 10 maximal (i.e. 0¼ no drug
liking, 10¼maximal drug liking)). Similar to the BLMRS,
these were each 10 cm in length, and subjects were asked to
quantify these terms by marking the line. The outcome mea-
sure was the distance to the marker on each scale.
Bowdle visual analogue scales. Psychedelic eﬀects were
monitored by an adapted version of the visual analogue
scales (13 items, each 10 cm in length), originally described
by Bowdle et al. (1998). Individual scales were aggregated to
scores for ‘feeling high’, ‘drowsy’, ‘internal perception’
(reﬂecting inner feelings not corresponding to reality) and
‘external perception’ (reﬂecting a misperception of an external
stimulus or a change in the awareness of the subject’s sur-
roundings) (Zuurman et al., 2008).
Statistical analyses
The pharmacodynamic parameters were analyzed by mixed
model analyses of variance (using SAS PROC MIXED, SAS
9.1.3 for Windows, SAS Institute, Inc., Cary, NC, USA) with
treatment, time and treatment by time as ﬁxed eﬀects, with
subject, subject by time and subject by treatment as random
eﬀects, and with the baseline value as covariate, where base-
line was deﬁned as the average of the available values
obtained prior to dosing. Treatment eﬀects are reported as
the contrasts between the four treatments, where the average
of the measurements up to the last time point was calculated
within the statistical model. Contrasts are reported along with
95% conﬁdence intervals (CI) and analyses are two-sided
with a signiﬁcance level of 0.05. Statistical evaluation of the
pharmacokinetics was performed with GLM Repeated
Measures Analysis of Variance (ANOVA, using SPSS 11.5
for Windows).
Results
Pharmacokinetics
MDMA and MDA kinetics did not diﬀer between MDMA
alone and MDMA plus THC conditions. Mean MDMA
maximal plasma concentrations (SEM) were on average
213.3 7.9mg/l 105min after drug administration and
showed minimal decline during the sampling period (on
average 168.3 5.4 mg/l 300min after drug administration).
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Mean MDA plasma concentrations on average rose to
12.0 0.5mg/l 300min after drug administration.
Plasma THC concentrations and its two most important
metabolites (11-OH-THC and 11-nor-9-carboxy-THC) did
not diﬀer between the THC alone and MDMA plus THC
conditions (Table 2). THC and 11-OH-THC consistently
showed peak concentrations directly after administration
and declined thereafter, whereas 11-nor-9-carboxy-THC con-
centrations inclined throughout the sampling period
(Dumont et al., 2009).
Pharmacodynamics
Only signiﬁcant results are mentioned in this section unless
noted otherwise. The main eﬀects of treatment, time and
treatment by time as well as drug condition comparisons
are summarized in Table 3. For the drug condition compar-
isons, reported are mean change, 95% CI and corresponding
p-values.
Body sway. Body sway was increased, that is, postural
position was impaired, in all drug conditions compared with
placebo. THC alone as well as co-administration of THC plus
MDMA increased body sway compared with the MDMA
alone condition.
Eye movements. Although smooth pursuit eye movements
(psychomotor accuracy) were not signiﬁcantly impaired in
any drug condition compared with placebo, MDMA and
THC showed opposite eﬀects on this measure: co-
administration of MDMA increased smooth pursuit eye
movements compared with the THC administration.
Psychomotor speed and sedation/arousal were assessed by
saccadic eye movements (respectively peak saccadic velocity
(PV) and reaction time). PV was increased in the MDMA
condition as well as in the MDMA plus THC condition com-
pared with the placebo and the THC condition. THC did not
aﬀect PV. Saccadic reaction time did not show a signiﬁcant
main eﬀect of drug administration.
Rotor pursuit task. The Rotor Pursuit task (Figure 1) per-
formance was signiﬁcantly impaired in the THC condition
and the MDMA plus THC condition compared with the pla-
cebo and MDMA condition. MDMA alone did not aﬀect the
Rotor Pursuit task.
Eighteen word list. Immediate recall of words was impaired
in all drug conditions compared with placebo. Delayed recall
and delayed recognition did not show a signiﬁcant main eﬀect
of drug administration (Figure 2).
N-back task. Performance on the 1-back task was impaired
in the THC condition and MDMA plus THC condition com-
pared with the placebo and MDMA condition.
Performance on the 2-back test did not show a signiﬁcant
main eﬀect of drug condition, although drug condition com-
parisons revealed a trend for impairment of 2-back perfor-
mance in the THC condition compared with the MDMA
condition (p¼ 0.053).
Co-administration of MDMA plus THC impaired 3-back
performance compared with placebo. THC administration
showed a trend for impairment of 3-back performance com-
pared with placebo (p¼ 0.055) (Figure 2).
Bond and Lader Mood Rating Scale. Subjective alertness
was reduced in the THC condition compared with the placebo
and the MDMA condition. Although co-administration of
MDMA plus THC attenuated this reduction in alertness com-
pared with the THC condition, subjective alertness was still
reduced in the MDMA plus THC condition compared with
placebo. Subjective contentedness was reduced in the THC
condition compared with the placebo as well as the MDMA
condition. Co-administration of MDMA plus THC abolished
this eﬀect: contentedness after co-administration did not
diﬀer compared with the placebo or the MDMA condition.
Subjective calmness was reduced in the MDMA condition
and the MDMA plus THC condition compared with the pla-
cebo and THC condition. THC did not aﬀect calmness rat-
ings (Figure 3).
Drug liking and Drug strength scale. ‘Drug liking’ ratings
were increased in the MDMA condition and MDMA plus
THC condition compared with the placebo and THC condi-
tion. ‘Drug strength’ ratings were increased after all drug
conditions compared with placebo. Co-administration of
THC plus MDMA further increased ratings of drug strength
compared with the MDMA condition.
Motivation was decreased in the THC condition compared
with the placebo, MDMA, and MDMA plus THC condition.
In other words, co-administration of MDMA with THC
reversed the THC-induced reduction of motivation.
Bowdle scale. All drug conditions increased ratings of
internal and external perception compared with placebo.
Co-administration of THC plus MDMA increased both inter-
nal and external perception compared with the placebo as
well as MDMA condition, and external perception also
increased compared with the THC condition. Ratings of ‘feel-
ing high’ were increased in all drug conditions compared with
placebo. ‘Feeling high’ ratings showed a more robust increase
in the THC condition compared with the MDMA condition,
and co-administration of THC plus MDMA further increased
subjective ‘feeling high’ compared with the MDMA condition
(but not compared with the THC condition). Feeling ‘drowsy’
scores were increased in the THC as well as the MDMA plus
THC condition compared with placebo.
Discussion
This study assessed the cognitive and subjective eﬀects of
co-administration of MDMA and THC in humans, a fre-
quent recreational drug combination. As MDMA is a
Table 2. THC, 11-OH-THC and 11-nor-9-carboxy-THC plasma concentra-
tions, 5min after drug administration (in ng/ml): [mean (SEM)]
Condition Dose THC 11-OH-THC
11-nor-
9-carboxy-THC
THC 4mg 59.7 (5.6) 2.8 (0.9) 8.4 (0.8)
MDMAþTHC 53.8 (6.9) 2.9 (0.8) 9.2 (1.2)
THC 6mg (1st) 84.5 (9.0) 3.7 (1.0) 16.0 (1.9)
MDMAþTHC 84.6 (8.6) 4.7 (1.0) 18.5 (1.7)
THC 6mg (2nd) 74.8 (6.9) 4.8 (1.2) 20.6 (1.5)
MDMAþTHC 73.3 (7.1) 6.9 (1.3) 21.7 (2.6)
THC: 9-tetrahydrocannabinol; MDMA: 3,4-methylenedioxymethamphetamine.
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psychostimulant, while THC generally impairs psychomotor
function, psychomotor eﬀects of these substances separately
were expected to be attenuated after co-administration.
However, results show that MDMA generally could not
attenuate THC’s impairment of psychomotor function.
Rotor pursuit performance was impaired by THC admin-
istration. This is in agreement with previous ﬁndings, where
THC moderately impaired driving-related performance
(Weinstein et al., 2008), and actual driving behaviour
(Ramaekers et al., 2000). THC also robustly impaired pos-
tural stability, an eﬀect that has been reported previously
(Zuurman et al., 2008). MDMA had no eﬀect on rotor pur-
suit performance, but it increased body sway, albeit to a lesser
extent than THC. Co-administration of MDMA and THC
further impaired rotor pursuit performance and postural sta-
bility compared with MDMA, but not compared with THC,
indicating that the detrimental eﬀects of THC prevailed.
Direct comparison of the MDMA condition with the THC
condition also showed that the eﬀect of THC on rotor pursuit
performance and postural stability was more robust.
Although psychomotor performance was impaired by
THC, THC did not aﬀect eye movements, which conﬁrms pre-
vious reports (Ploner et al., 2002; Zuurman et al., 2008), and is
congruent with cannabinoid receptor distribution patterns: eye
movements are primarily driven by brain stem areas, which
show little CB1 receptor expression (Zuurman et al., 2008).
MDMA on the other hand increased saccadic peak velocity
but not accuracy, which is also in line with a previous study
(Dumont et al., 2007). Eﬀects of co-administration of MDMA
and THC were similar to those observed in the MDMA only
condition.
The eﬀects of THC andMDMA onmemory were complex.
Both THC and MDMA impaired word recall: immediate
recall of words was signiﬁcantly reduced in both single
drug conditions. Delayed recall and recognition were unaf-
fected by drug administration. Previous results regarding
THC eﬀects on memory generally are congruent with our
results, where THC impaired immediate (Curran et al., 2002;
D’Souza et al., 2004; Hart et al., 2001; Heishman et al., 1997;
Morrison et al., 2009) but also delayed recall (Curran et al.,
2002; D’Souza et al., 2004) of a word list. MDMA’s impair-
ment of word list performance in the current study was
comparable in size to the eﬀects reported earlier. However,
in a previous study the reduction of immediate recall failed
to reach signiﬁcance, whereas impaired delayed recall did
(Dumont et al., 2008). Reports by Kuypers and Ramaekers
(2005, 2007) showed acute impairment of both immediate
and delayed recall of words as well as spatial memory by
MDMA. Co-administration of MDMA and THC did not
exacerbate impairment of word list recall compared with
either drug alone.
As previous (animal) research showed that
co-administration of MDMA and THC induced a synergis-
tic impairment of working memory (Young et al., 2005),
co-administration was expected to show additive impairment
on tests of working memory compared with single drug
eﬀects. However, the eﬀects of these substances on the
N-back task, a test of working memory, were subtle and
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did not appear to be additive, although the complexity of
THC-induced impairment warrants further research regard-
ing this topic. The eﬀects of THC on the N-back working
memory task were time and dose dependent, where THC gen-
erally induced a robust but short-lived impairment of working
memory. The 2-back condition did not show an eﬀect of drug
administration. THC impaired performance in the 1-back
condition and showed a trend of impairment (p¼ 0.055) in
the 3-back condition, congruent with previous reports where
THC impaired working memory (D’Souza et al., 2004; Ilan
et al., 2004), although Curran et al. (2002) found no eﬀect of
THC on working memory using the serial sevens task. The
discrepancy of THC eﬀects on 2- and 3-back performance
versus the 1-back performance may be explained by the fact
that the 1-back condition may assess psychomotor function
rather than working memory as subjects only have to locate
the dot that lit-up, that is, performance will primarily be
determined by the time the subject needs to reach the
target, rather than correctly memorizing which dot lit up n
times before. In this sense, these results may reﬂect THC-
induced impairment of psychomotor function rather than
working memory. A recent systematic literature review also
showed complex eﬀects of THC/cannabis on working
memory, with possible indications for an inverse dose–
response relationship (Zuurman et al., 2009).
N-back performance was unaﬀected in the MDMA
condition. Co-administration of MDMA and THC impaired
1-back and 3-back performance. Although THC alone did
not signiﬁcantly impair 3-back performance, the observed
trend suggests that the impairment of n-back performance
after co-administration was driven primarily by THC, and
co-administration of MDMA and THC did not, contrary to
our hypothesis, exacerbate single drug-induced memory
impairment.
These results suggest that THC may exert much of its cog-
nitive impairment via a common mechanism of reduced alert-
ness. This is in line with its classiﬁcation as a relaxant/sedative
drug, and with reports that show that subjects are able to
compensate for these impairments at the cost of greater
eﬀort (Curran et al., 2002). The stimulant eﬀects of MDMA
may attenuate this eﬀect, but could not overcome THC-
induced impairments in the current study. Subjective ratings
show that the subjects were aware of these impairments: THC
increased subjective ratings of feeling ‘drowsy’, and reduced
ratings of ‘motivation’ and ‘alertness’. Co-administration of
MDMA reversed the THC-induced reduction of subjective
motivation, and attenuated the reduction of alertness by
THC, although the latter was still signiﬁcantly decreased
after co-administration compared with placebo. The fact
that subjects reported that THC reduced subjective alertness
may be of signiﬁcance when driving while intoxicated.
Subjects who report reduced alertness are likely to adapt
their behaviour, thus reducing the risk of traﬃc accidents
(Ronen et al., 2008; Sewell et al., 2009).
Subjective eﬀects further suggest that the combination
may be popular because it enhances the pleasurable subjective
eﬀects of each drug alone. Both THC and MDMA-induced
robust subjective drug eﬀects and increased subjective ratings
of ‘feeling high’, internal perception (reﬂecting inner feelings
not corresponding to reality) and external perception
(reﬂecting a misperception of an external stimulus or a
change in the awareness of the subject’s surroundings), and
both were comparable in ‘drug strength’. MDMA increased
subjective ‘drug liking’, whereas in the THC condition ‘drug
liking’ ratings appeared inversely dose-related: ‘drug liking’
was robustly decreased after the high THC dose (6mg) com-
pared with the lower dose (4mg). Congruent with drug liking
ratings, subjective contentedness was dose-dependently
reduced in the THC condition. This apparent inverse dose–
response relationship is in line with an overall assessment of
the literature on the eﬀects of cannabis/THC (Zuurman et al.,
2009). Co-administration of THC and MDMA enhanced sub-
jective drug eﬀects: ratings of ‘drug strength’, ‘internal and
external perception’ and ‘feeling high’ were increased com-
pared with the MDMA condition, whereas ratings of ‘con-
tendedness’, ‘external perception’ and ‘drug liking’ were
increased compared with the THC condition. The perceived
increase of drug strength, combined with enhanced sensory
drug eﬀects, without an unacceptable decrease of cognitive
function, oﬀers a plausible incentive for combining canna-
bis with ecstasy in recreational settings. Some caution
should be taken into account, as the ‘drug liking’ ratings
after co-administration were comparable to MDMA alone.
However, MDMA alone increased drug liking rating to
near maximal values, which may point to ceiling eﬀects
explaining this discrepancy.
Some limitations should be addressed. In the current
study, some eﬀects of THC on memory failed to reach signif-
icance (although trends were observed). It is likely this may be
related to the short-lived eﬀects of THC on memory. As can
be seen in Figure 2, the eﬀects of THC on memory were
robust around 15min but were diminished 60min after drug
administration, a pattern that could be observed after all
three doses, although memory was assessed 60min after the
third dose only. This suggestion is congruent with previous
studies showing that THC impaired N-back task performance
20 but not 60min after THC administration (Ilan et al., 2004),
and that THC-induced impairment of immediate recall was
the strongest in the period immediately after drug adminis-
tration (Heishman et al., 1997). Future studies with more
frequent test intervals relative to drug administration are
recommended to elucidate the time proﬁle and possible
dose dependency of THC-induced memory impairment.
Alternatively, as we recruited volunteers with considerable
cannabis use (on average two or more exposures per week),
subjects may have developed tolerance to some of the cogni-
tive eﬀects of cannabis (D’Souza et al., 2008).
This also points to another limitation of our study. To
maintain a stable eﬀect level of THC during co-administra-
tion of MDMA, we assessed the eﬀects of a single dose of
MDMA and three consecutive vaporized THC doses. Eﬀects
may diﬀer depending on the dose assessed, the timing of drug
administration, the order in which drugs are used and the
method of drug delivery (i.e. vaporized THC vs smoked can-
nabis). Our approach cannot be considered fully representa-
tive of all modes of combined drug use in practice. In general,
the circumstances in which these substances are normally
used cannot be fully recreated in the laboratory, although
they may inﬂuence the eﬀects of MDMA (Sumnall et al.,
2006). However, the doses of each drug used in this study
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were similar to normal recreational use. In this sense, the
current study sets a relevant benchmark for future evaluations
of other dose combinations.
In conclusion, our study shows that co-administration of
MDMA and THC did not exacerbate single drug-induced
cognitive impairment. Compared with MDMA (100mg),
THC (4, 6 and 6mg) induced more robust impairment of
cognitive function. Subjective eﬀects show that subjects
were aware of these impairments, and that the combination
of THC with MDMA enhanced the perceived drug strength
and desired drug eﬀects compared with the MDMA condi-
tion. These results suggest that cannabis increases the desired
eﬀects of ecstasy without an unpredictable increase in cogni-
tive impairment, which may explain the widespread recrea-
tional use of this combination.
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